title: Biochemical and pathological study of endogenous 1-benzyl-1,2,3,4-tetrahydroisoquinoline-induced parkinsonism in the mouse.
abstract: We administered 1-benzyl-1,2,3,4-tetrahydroisoquinoline (1-BnTIQ; 80 mg/kg, i.p.), an endogenous neurotoxin known to cause bradykinesia, the Parkinson's disease-like symptom, in order to obtain biochemical and pathological evidence of behavioral abnormalities. Immunohistochemical analysis demonstrated that 1-BnTIQ did not decrease the number of tyrosine hydroxylase-positive cells in the substantia nigra. Biochemical analysis demonstrated significantly increased striatal dopamine (DA) content, while DA metabolites in the striatum remained at control levels. We concluded that the 1-BnTIQ-induced bradykinesia has a different mechanism of action than that underlying the MPTP-induced depletion of striatal DA neurons.
authors: Department of Neuroscience, Showa Pharmaceutical University, 3-3165 Higashitamagawagakuen, Machida, 194-8543, Tokyo, Japan.
authors: K
authors: K
authors: Abe
authors: K
authors: K
authors: Taguchi
authors: T
authors: T
authors: Wasai
authors: J
authors: J
authors: Ren
authors: I
authors: I
authors: Utsunomiya
authors: T
authors: T
authors: Shinohara
authors: T
authors: T
authors: Miyatake
authors: T
authors: T
authors: Sano
mesh_terms: D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000008:administration & dosage / Q000494:pharmacology; D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D004298:Dopamine / Q000031:analogs & derivatives* / Q000378:metabolism; D004334:Drug Administration Schedule; D006719:Homovanillic Acid / Q000378:metabolism; D006897:Hydroxyindoleacetic Acid / Q000378:metabolism; D007546:Isoquinolines / Q000008:administration & dosage / Q000633:toxicity*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009419:Nerve Tissue Proteins / Q000032:analysis; D010300:Parkinson Disease / Q000378:metabolism / Q000473:pathology; D010302:Parkinson Disease, Secondary / Q000139:chemically induced*; D012701:Serotonin / Q000378:metabolism; D013378:Substantia Nigra / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D044005:Tetrahydroisoquinolines; D014446:Tyrosine 3-Monooxygenase / Q000032:analysis
chemical_list: D007546:Isoquinolines; D009419:Nerve Tissue Proteins; D044005:Tetrahydroisoquinolines; D015102:3,4-Dihydroxyphenylacetic Acid; D012701:Serotonin; D006897:Hydroxyindoleacetic Acid; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D014446:Tyrosine 3-Monooxygenase; C001746:3-methoxytyramine; D004298:Dopamine; C084924:1,2,3,4-tetrahydro-1-(phenylmethyl)isoquinoline; D006719:Homovanillic Acid